Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

Summary

This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

Timeline

Start

2018-04-02

Primary completion

2019-03-08

Completion

2019-06-27

Drugs

Indications